Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Klaus Frueh
Fred Hutchinson Cancer Research Center, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
TomegaVax
Other : Exclusively licensed technology, through institution (OHSU considers this an SFI); 0-5K & Founder, President/CSO; 0-5K
The research involves exclusively licensed technology of which Dr. Frueh is inventor and that is licensed to a company in which Dr. Frueh has a financial interest.
The Pacific Northwest Prostate Cancer SPORE
Prostate cancer (PC) is a major cause of cancer incidence and mortality in US men. This year alone 240,890 men will be diagnosed and 33,720 will die of the disease; and the annual number of men dying from PC is increasing. This highlights the urgent need for translational PC research to uncover the underlying genetic and genomic factors and pathways that drive PC toward its lethal phenotype, including resistance to therapy.
Filed on August 04, 2015.
Tell us what you know about Klaus Frueh's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Klaus Frueh”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Klaus Frueh | Fred Hutchinson Cancer Research Center | Conflict of Interest | Vir Biotechnology, Inc. | $0 - $4,999 |
| Klaus Frueh | Oregon Health & Science University | Conflict of Interest | Vir Biotechnology, Inc. (formerly called TomegaVax, Inc.) | Value cannot be readily determined |
| Klaus Frueh | Oregon Health & Science University | Conflict of Interest | TomegaVax, Inc. | $0 - $4,999 |
| Klaus Frueh | Fred Hutchinson Cancer Research Center | Conflict of Interest | Vir Biotechnology, Inc. | Value cannot be readily determined |
| Klaus Frueh | Fred Hutchinson Cancer Research Center | Conflict of Interest | Vir Biotechnology, Inc. | $150,000 - $199,999 |
| Klaus Frueh | Oregon Health & Science University | Conflict of Interest | Vir Biotechnology, Inc. (formerly called TomegaVax, Inc.) | $0 - $4,999 |
| Klaus Frueh | Oregon Health & Science University | Conflict of Interest | Vir Biotechnology, Inc. (formerly called TomegaVax, Inc.) | $150,000 - $199,999 |
| Klaus Frueh | Oregon Health & Science University | Conflict of Interest | Vir Biotechnology, Inc. (formerly called TomegaVax, Inc.) | Value cannot be readily determined |
| Klaus Frueh | Oregon Health & Science University | Conflict of Interest | TomegaVax, Inc. | $0 - $4,999 |
| Klaus Frueh | Fred Hutchinson Cancer Research Center | Conflict of Interest | TomegaVax | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.